ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

ClinicalTrials.gov ID: NCT02718300

Public ClinicalTrials.gov record NCT02718300. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 16, 2026, 3:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Study identification

NCT ID
NCT02718300
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Incyte Corporation
Industry
Enrollment
74 participants

Conditions and interventions

Interventions

  • Parsaclisib Drug
  • Ruxolitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 7, 2017
Primary completion
Jan 27, 2021
Completion
Apr 28, 2022
Last update posted
Apr 30, 2024

2017 – 2022

United States locations

U.S. sites
39
U.S. states
23
U.S. cities
36
Facility City State ZIP Site status
Birmingham Hematology & Oncolgy Associates Llc Birmingham Alabama 35223
Mayo Clinic Arizona Scottsdale Arizona 85259
Alta Bates Medical Center Berkeley California 94704
City of Hope National Medical Center Duarte California 91010
California Cancer Associates For Research and Excellence Fresno California 93720
University of Southern California Los Angeles California 90033
UCLA School of Medicine Los Angeles California 90095
Pcr Oncology Pismo Beach California 93449
California Cancer Assoc. for Research and Excellence San Marcos California 92069
Georgetown University Hospital Washington D.C. District of Columbia 20007
Shands Hospital Gainesville Florida 32610
Emory University Atlanta Georgia 30322
University of Chicago Medical Center Chicago Illinois 60637
Indiana Blood and Marrow Transplantation Indianapolis Indiana 46237
McFarland Clinic Ames Iowa 50010
University of Kansas Cancer Center Westwood Kansas 66205
Norton Cancer Institute Louisville Kentucky 40202
Saint Agnes Hospital Baltimore Maryland 21229
Cancer Center For Blood Disorders Bethesda Maryland 20817
Massachusetts General Hospital Boston Massachusetts 02114
Washington University School of Medicine St Louis Missouri 63130
Summit Medical Group Florham Park New Jersey 07932
Hackensack University Medical Center Hackensack New Jersey 07601
New Mexico Cancer Care Alliance Albuquerque New Mexico 87106
Roswell Park Cancer Institute Buffalo New York 14263
Mount Sinai School of Medicine New York New York 10029
Columbia University Medical Center New York New York 10032
Memorial Sloan Kettering Cancer Center New York New York 10065
Montefiore Medical Center The Bronx New York 10467
Oncology Hematology Care, Inc. Cincinnati Ohio 45230
Cleveland Clinic Cleveland Ohio 44195
Oregon Health & Science University Portland Oregon 97239
Rush University Medical Center Nashville Tennessee 37203
Baylor Scott and White Research Institute Dallas Texas 75246
Md Anderson Cancer Center Houston Texas 77030
Cancer Care Centers of South Texas San Antonio Texas 78217
Renovatio Clinical Consultants Llc The Woodlands Texas 77380
Va Salt Lake City Health Care System Salt Lake City Utah 84112
Vista Oncology Inc Ps Olympia Washington 98506

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02718300, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 30, 2024 · Synced May 16, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02718300 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →